Seattle, WA, TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease, announces that Dr. Glynn Wilson, Chairman & CEO, will present at the NYC MedTech Program, a medical technology and life science forum founded by John Lieberman CPA, Managing Director of Perelson Weiner LLP, on Thursday June 14, 2012 at the offices of Kaye Scholer LLP in New York City. More information can be found at www.nycmedtech.com.
About NYC MedTech
NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries to have successful outcomes. This unique program not only brings together companies and investors but all people that are involved, including reporters, scientists, academia, trade organizations, international partners, etc. The NYC Medtech program introduces invited participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum. The NYC Medtech initiative was created and founded by John R. Lieberman at Perelson Weiner, LLP, along with Wendy Brown of Merrill Lynch and is sponsored by Kaye Scholer LLP.
About TapImmune Inc.
TapImmune Inc. (TPIV.OB) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system.